Laser Therapy in Women With Lichenoid Disorders (Liser)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04697563|
Recruitment Status : Recruiting
First Posted : January 6, 2021
Last Update Posted : January 11, 2022
|Condition or disease||Intervention/treatment||Phase|
|Lichen Sclerosus Et Atrophicus Lichen Planus||Device: Laser Device: Placebolaser||Not Applicable|
Background: Lichenoid Disorders (LD) include VLS (Vulvar lichen sclerosus) and LP (Lichen planus). VLS and LP are chronic skin diseases that usually affect the anogenital region. Both can cause vulvar itching, burning and pain and can lead to urinary and sexual dysfunction. Current treatment options are unsatisfactory. Vulvovaginal laser therapy might be an effective treatment option.
Study aim: To study the effectiveness of non-ablative vulvovaginal laser therapy for women with lichenoid disorders.
Design: Randomized double-blinded placebo- controlled clinical study
Study Population: Women diagnosed with LD will be recruited from a specialized University outpatient clinic.
Study groups: Participants will be randomized (1:1). Intervention group: Laser therapy (2 treatments), plus ongoing therapy Control group: Sham laser therapy (2 treatments) plus ongoing therapy
Sample size Total 40 patients Primary study outcome: Visual analogue scale (VAS) composite score in regard to LD Secondary study outcomes: quality of life (QoL) (Skindex questionnaire); Treatment discomfort/ pain (VAS); Patient treatment satisfaction (Questionnaire to ask for treatment satifsaction: ZUF-8); Subjective improvement (Patient global impression of improvement- PGI-I), clinical LS score, histological appearance
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomized double-blinded placebo- controlled clinical study|
|Masking:||Double (Participant, Investigator)|
|Masking Description:||The person who performs the laser treatment is unaware of the treatment given The laser devices can be used as a placebo laser by blocking the laser beam with a plug|
|Official Title:||Laser Therapy in Women With Lichenoid Disorders: A Randomized Controlled Trial|
|Actual Study Start Date :||November 17, 2020|
|Estimated Primary Completion Date :||November 17, 2022|
|Estimated Study Completion Date :||November 17, 2022|
Active Comparator: Laser
Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia.
Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions.
real laser beam administered
Other Name: Fotona Smooth XS laser
Placebo Comparator: Placebo Laser
Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the "normal" probe. The treating physician will not be aware of the study allocation and the type of probe in use.
no laser beam admitted
Other Name: Fotona Smooth XS laser placebo
- subjective bother of lichenoid disorders (LD) [ Time Frame: 3 months ]
A visual analogue scale (VAS) is used for assessment for the subjective bother of LD symptoms. Patients are asked to indicate the degree of each of the three following LD symptoms on a scale ranging from 0 (no symptoms) to 10 (worst possible symptoms):
genital symptoms of itching, burning and vaginal pain resulting in a composite VAS score
- Treatment discomfort / pain [ Time Frame: 3 months ]patients are asked to indicate the degree of discomfort or pain during laser therapy on a visual analogue scale (VAS) ranging from 0 (no discomfort/pain) to 10 (worst possible discomfort/pain)
- subjective symptoms of lichenoid disorders [ Time Frame: 3 months ]The Skindex questionnaire will be used to evaluate patients' subjective symptoms of lichenoid disorders
- Patient Global Impression of Improvement- PGI-I [ Time Frame: 3 months ]The PGI-I scales are robust and valid instruments to assess disease severity, bother and improvement after treatment in women and will be used to determine the Patient Global Impression of Improvement. The PGI-I consists of a 7-likert-scale with 7 being the worst bother.
- Patient Global Impression of Severity- PGI-S [ Time Frame: 3 months ]The Patient Global Impression of Severity (PGI-S) is a global index that may be used to rate the severity of a specific condition (a single-state scale). The PGI scales are robust and valid instruments to assess disease severity, bother and improvement after treatment and will be used to determine the Patient Global Impression of Severity. The PGI scales are robust and valid instruments to assess disease severity, bother and improvement after treatment. The patient can choose from 4 answers including none, mild, moderate and severe.
- architectural changes [ Time Frame: 3 months ]The vulva will be inspected and structural changes due to LD will be recorded. The score is based on the publication from Günthert et al. The score records signs of erosions, hyperkeratosis, rhagades, synechia, stenosis, and atrophy of the vulva. The questionnaires is based on a 29-item version; the higher the score the more pronounced are the clinical signs.
- Histological analysis of LD [ Time Frame: 3 months ]Lichenoid disorders show epidermic atrophy, sclerosis and a lymphocytic based dermal inflammation. Hyperkeratosis and dermal inflammation will be evaluated both from the histological probe before and after treatment. Each item will be scored from 1-3, mild, moderate and severe. A higher score indicates more severe expression of LD.
- Patient satisfaction with treatment/ inpatient management [ Time Frame: 3 months ]Patient satisfaction will be evaluated with the "Fragebogen zur Patientenzufriedenheit - ZUF8". The German version of the original "Client Satisfaction Questionnaire-CSQ8", is a validated tool for measuring global patient satisfaction at the end of inpatient treatment. he Zuf-8 is an 8-items questionnaire to assess satisfaction in patients undergoing inpatient treatment. At 3 months treatment satisfaction will be assessed using an adopted version of the questionnaire. The lower the score the higher is the patient satiscation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04697563
|Department of Obstetrics, Medical University Graz||Recruiting|
|Graz, Austria, 8045|
|Contact: Daniela Ulrich, MD, PhD +4331638581437 firstname.lastname@example.org|
|Principal Investigator: Daniela Gold, M.D.|
|Sub-Investigator: Karl Tamussino, MD|
|Sub-Investigator: Gerda Trutnovsky, MD|
|Sub-Investigator: Nadja Taumberger, MD|
|Sub-Investigator: Anna Schütz, MD|